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RESEARCH NOTE
Granulomatosis with polyangiitis: 
a 17 year experience from a tertiary care 
hospital in Pakistan
Omar Irfan1*, Haris Khan1, Zarrar Khan2, Alina Ashraf3, Rimsha Ahmed3, Javaid Ahmad Khan4 
and Ali Bin Sarwar Zubairi4
Abstract 
Objective: Granulomatosis with Polyangiitis (GPA) is an autoimmune, multi-system, small and medium vessel vascu-
litis with granulomatous inflammation. Aim of this study was to assess the clinical and radiological presentations of 
patients with GPA amongst the Pakistani population. It is a single centre retrospective single observation study.
Results: Study was conducted at the Aga Khan University Hospital, Karachi with records were reviewed from January 
2000 to December 2017. Definitive diagnosis was made using a combination of serological anti-neutrophil cytoplas-
mic antibody (ANCA) testing along with the clinical and radiological presentation. A total of 51 patients met the diag-
nostic criteria in the time frame of the study. There were 23 males and 28 females with mean age of 44.0 ± 17.8 years 
on presentation. Arthritis was the most common symptom present in 41.2% of the cases followed by cough in 32.0%. 
Sixteen patients showed pulmonary infiltrates on chest X-ray. C-ANCA was positive in all of the patients compared 
with 21.6% p-ANCA positivity. A total of 13 biopsies were done. The median Birmingham Vasculitis Activity Score was 
12. We report a 17.6% mortality rate with 5 deaths occurring due to respiratory failure. GPA is a diagnostic challenge 
leading to late diagnosis which can contribute to significant morbidity and mortality specially in the Third World.
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Introduction
GPA is an autoimmune small vessel vasculitis associated 
with anti-neutrophil cytoplasmic antibodies (ANCA). 
The clinical manifestations include systemic necro-
tising vasculitis, necrotising glomerulonephritis and 
necrotising granulomatous inflammation. GPA was first 
described in the literature in a case report in the late 
nineteenth century and was previously known as Wegen-
er’s Granulomatosis [1]. While it is uncommon overall, a 
significant geographical variation has been observed in 
the prevalence of this disease. A latitudinal gradient has 
been identified with increasing trend in prevalence as the 
distance from the Equator increases [2].
In GPA, ANCA is mainly directed against Proteinase 
3 (PR3); there is strong evidence from various in  vitro 
studies that ANCA plays a crucial role in the mediation 
of small vessel vasculitis [3]. GPA usually starts as a local-
ized granulomatous inflammation of the respiratory tract 
that later generalizes into small vessel vasculitis [4, 5]. 
Older age, pulmonary and kidney involvement are fea-
tures associated with poor prognosis and increased mor-
tality [6]. The first case of GPA was reported by a German 
clinician, Heinz Klinger in 1931 who believed it to be 
a variant of polyarteritis nodosa, but it was Friedrich 
Wegener who proposed this as a separate pathology 
based upon the post mortem findings seen in three of his 
patients [7, 8] Several large case series on GPA have been 
published from various countries, with the largest series 
reporting 445 patients from Germany [9]. This is the first 
large institutional experience on the clinical manifesta-
tions of GPA patients amongst the Pakistani population. 
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We report a series of 51 cases from our institution. Our 
study focuses on the clinical and imaging features of GPA 
with the hope that it will assist clinicians in better iden-
tifying and managing this condition. We also summarize 
the compare the clinical features of our patients with 
those from other ethnic group studies from literature in 
a tabulated form.
Main text
Methods
A retrospective, observational study was conducted at 
the Aga Khan University Hospital (AKUH), Karachi. 
Records of all patients diagnosed with GPA from Janu-
ary 2000 to December 2017 were reviewed. Age, gender, 
clinical features at the time of diagnosis, laboratory and 
histo-pathological findings, imaging, type of treatment, 
response to treatment and complications were collected 
in a predesigned questionnaire. The files were retrieved 
using international classification of diseases-9 (ICD-9) 
coding. No experimentation on Human and animals was 
done. This study was approved by the local ethical com-
mittee of the institution. SPSS IBM version 20 was uti-
lized to analyze the data. Each categorical item from the 
questionnaire was summarized by frequency count and 
percentage.
We used non-standardized criteria to diagnose the 
disease. The 1990 American College of Rheumatology 
and 2012 Chapel Hill Consensus Conference criteria for 
the classification of the vasculitis have been accepted 
[6], however they are not intended to be used as diag-
nostic criteria. The ACR criteriawas devised before the 
widespread recognition of microscopic polyangiitis as a 
separate disease as well as prior to recognition of anti-
neutrophil cytoplasmic autoantibody (ANCA) testing 
as a significant diagnostic tool. Therefore being a non 
invasive test, we used serological evaluation as the initial 
step for diagnosis of GPA at our institution. C-ANCA is 
known to have sensitivity of 91% and specificity of 99% 
for GPA [7]. Birmingham Vasculitis Activity Score ver-
sion 3 (BVAS-v3) was used to determine the disease 
activity. Outcomes recorded were death, cause of death 
and number of relapses.
Results
During the study period, 51 patients diagnosed with 
GPA were identified. The mean age of presentation was 
44.0 ± 17.8  years with 23 males and 28 females. The 
respiratory system was most commonly affected in 41 
(80.4%) patients, followed by renal in 28 (54.9%), Ear 
Nose and Throat (ENT) in 25 (49.0%), musculoskel-
etal system in 22 (43.1%), nervous system in 9 (17.6%), 
integumentary system in 8 (15.7%) and ocular system 
in 6 (11.8%) patients. Arthralgia was the most common 
presenting symptom seen in 21 patients followed by 
cough in 16 patients. The clinical symptoms on presenta-
tion are as shown in Table 1.
All of the selected patients underwent both p-ANCA 
and c-ANCA on initial work up. The c-ANCA was posi-
tive in all patients whilst only 11 patients were positive 
with p-ANCA. Thirty three patients had a raised ESR 
(> 20  mm/h). The radiological findings are outlined in 
Table 2.
The most common finding on chest X-ray was pulmo-
nary infiltrates seen in 16 patients (31.4%), followed by 
pulmonary nodules, alveolar hemorrhages and cavita-
tions in 9 patients each. A total of 13 biopsies were done 
which included 7 renal, 3 nasal, 2 lung and 1 skin speci-
men. Four renal biopsies showed crescenteric glomerulo-
nephritis, while focal necrotizing glomerulonephritis was 
noted in 3 specimens. Chronic granulomatous remod-
eling along with necrotic change was well appreciated 
in all the nasal biopsies. A mixed picture of acute and 
chronic inflammation with scattered multinucleated 
Table 1 Clinical manifestations of the patients with GPA
Clinical manifestations Frequency (n) Percentage (%)
ENT 25 49.0
 Rhinosinusitis 6 11.8
 Mucosal ulcers 1 2.0
 Epistaxis 7 13.7
 Hearing loss 9 17.6
 Collapsed nasal bridge/sad-
dle nose deformity
2 3.9
Pulmonary 41 80.4
 Cough 16 31.9
 Hemoptysis 9 17.6
 Chest discomfort 7 13.7
 Dyspnea 5 9.8
 All 4 7.8
Renal 28 55.0
 Hematuria 11 21.6
 Renal failure 17 33.3
 Ocular 6 11.8
 Conjunctivitis 4 7.8
 Episcleritis/uveitis 2 3.9
Neurological 9 17.6
 Cranial nerve palsies 4 7.8
 Peripheral neuropathy 5 9.8
Musculoskeletal 22 43.1
 Arthritis/arthralgia 21 41.2
 Myalgia 1 2.0
Cutaneous 8 15.7
 Purpura/ecchymosis 6 11.8
 Ulceration 2 3.9
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giant cells and vasculitis could be identified in the lung 
and skin biopsy results.
Forty five patients received a pulse dose (1  g/day) of 
intravenous methyl prednisone. Remission was achieved 
in 32 patients while 9 patients relapsed. Prednisolone 
was the most common agent used for induction therapy 
in 32 (62.6%) patients followed by cyclophosphamide 
in 11 (21.6%) patients. Other therapies include Metho-
trexate, Rituximab, Plasma exchange and Azathioprine. 
Prednisolone was the most common agent used for 
maintenance therapy in 41 (80.3%) patients followed by 
azathioprine in 8 patients (15.7%). The complications that 
developed after the initiation of treatment were divided 
into 3 categories: opportunistic infections, malignancy 
and cytopenia. Sixteen patients developed opportunis-
tic infections. Malignancies and cytopenia were noted 
in four each. Nine patients passed away during the study 
period; of these 5 deaths occurred due to respiratory fail-
ure, 3 deaths happened due to sepsis and 1 patient suc-
cumbed to heart failure. The median BVAS-v3 score at 
presentation among all patients was 12.0 with range from 
4.0 to 24.0. BVAS-v3 score was higher among patients 
who expired compared to those who survived (14.1 vs. 
11.1, P > 0.05). However the difference was insignificant 
therefore we cannot conclude if the BVAS-v3 score at 
presentation is useful in determining severity of disease 
and in determining prognosis.
Discussion
This study, documenting 17  years of experience, is the 
most comprehensive, single-institution study describing 
the clinical and radiological characteristics, management, 
and outcome of patients with GPA from the Pakistani 
population. Respiratory manifestations were recorded 
in 80% of our patients as compared to 50% involvement 
observed in the literature whilst alveolar hemorrhage, 
lung nodules, and respiratory failure were the key pre-
senting features of this condition [8]. The second organ 
system most commonly involved includes the kidneys 
with focal segmental necrotizing glomerulonephri-
tis being the most consistently presenting feature [10]. 
More than half of the patients (55%) in our study had 
renal manifestations and one-third of them developed 
renal failure. Our study reports 49% of the cases present-
ing with ENT manifestations. Hearing loss and epistaxis 
were the most frequent symptoms. Previously, more than 
70% of cases have been reported to have presented with 
signs related to ENT ranging from crusting rhinorrhea 
to damage of the facial cartilage causing deformities [11]. 
Other rare symptoms involved the mucocutaneous, nerv-
ous and ocular systems.
On radiological evaluation, 16 of 51 patients demon-
strated pulmonary infiltrates in the form of consolida-
tions making it the most common presentation in our 
setting. Cordier et al reported pulmonary infiltrates to be 
the second most common presentation making up 53% 
of the patient population in their study [12]. In 1990 the 
American College of Rheumatology endorsed a criterion 
for the diagnosis of GPA. One of the clauses of the cri-
teria was the presence of abnormal radiological findings 
on chest X ray [13]. Chest CT is considered superior to 
chest X-ray in the diagnosis of small vessel vasculitis [14]. 
Out of the 51 patients, 18 had an HRCT done. Six out of 
18 patients showed airspace consolidation, making it the 
most common finding. Multiple studies have shown that 
abnormal radiological findings are found in 50–75% of 
the population with GPA [15] with nodules and masses 
being the two most common radiographic manifesta-
tions. Studies have also labeled the presence of bronchi-
ectasis as a rare presentation [16] as supported by the 
presence of bronchiectasis in only 4 patients in our study.
Moving on to serological investigations, ANCA test-
ing has been employed as diagnostic criteria for GPA 
at our institution. Anti-neutrophilic cytoplasmic anti-
body (ANCA) sensitivity can be as low as 60% in local-
ized disease [17] whereas ANCA is both sensitive and 
specific for GPA being present in 80–90% of patients 
with systemic disease. Still, there are some reported 
cases where the ANCA was negative [18]. A previous 
study by Chloe et  al showed an 80% c-ANCA positiv-
ity [19]. Prednisolone and Cyclophosphamide were the 
most commonly used drugs for induction in 32 and 
11 patients respectively. For severe disease, plasma 
exchange in addition to oral corticosteroids and cyclo-
phosphamide administration has been recommended 
to halt the progression to end stage renal failure [20]. 
Oral corticosteroid therapy in conjunction with daily 
Table 2 Radiological manifestations of  the  patients 
with GPA
Parameters Frequency (n) Percentage (%)
Chest X-ray findings 51 100
 Pulmonary infiltrates 16 31.4
 Diffuse alveolar hemorrhage 9 17.6
 Nodules 9 17.6
 Cavitations 9 17.6
 Pleural effusion 4 7.8
 Normal 4 7.8
Chest CT findings 18 35.3
 Nodules or masses 2 3.9
 Airspace consolidation 6 11.8
 Cavitation 5 9.8
 Ground-glass  Appearance 1 2.0
 Bronchiectasis 4 7.8
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oral cyclophosphamide or intravenous pulsatile cyclo-
phosphamide is recommended for systemic disease 
with organ dysfunction [20]. We had 33 cases main-
tained with prednisolone.
A literature review revealed a relative paucity of stud-
ies available on ANCA associated vasculitis from the 
developing world. Our institution reported a 13 patient 
registry in 2004 [21]. A 20 case series of Rhinological 
manifestations of GPA was also reported from Rawal-
pindi in 2011 [22]. To our knowledge, this is the biggest 
experience from Pakistan. Our neighboring Country, 
India has reported three institutional experiences of 
60, 45 and 105 patients. They also assessed the disease 
activity and damage through the Birmingham Vasculitis 
Activity Score v.3 (BVAS v. 3) [23, 24]. The Indian series 
have been presented in Table 3 along with other ethnic 
groups Table 3. Compares the summaries of GPA series 
from literature. A comparable prevalence of organ sys-
tem involvements are seen. In our opinion, tertiary care 
centers need to maintain a registry of all the ANCA 
associated vasculitis cases so that their clinical pres-
entation and response to treatment can be well docu-
mented for our population.
Conclusion
The results from our study indicate that GPA is not 
uncommon in Pakistan. We believe that larger studies on 
GPA will assist physicians in timely diagnosis and man-
agement of the disease.
Limitations
A few notable shortcoming of our study include the small 
sample size making it difficult to develop significant asso-
ciations between variables. Likewise, we report data from 
only one tertiary care hospital of the country and so the 
results we present cannot be generalized due to the pos-
sibility of referral bias.
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